2b (Ibrutinib, PCI-32765), the first-in-class BTK inhibitor, is an orally available, highly potent, and irreversible ATP-competitive kinase inhibitor for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) [35,36]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.